Lead Product(s) : Vonafexor
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : OrbiMed Advisors
Deal Size : $42.5 million
Deal Type : Series C Financing
ENYO Pharma Secures €39M in Series C and FDA Clearance for Vonafexor
Details : Financing will support the Phase 2 Alpestria-1 study and profiling of EYP001 (vonafexor), a selective NR1H4 agonist, in Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Product Name : EYP001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 01, 2024
Lead Product(s) : Vonafexor
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : OrbiMed Advisors
Deal Size : $42.5 million
Deal Type : Series C Financing